Richardson Electronics, Ltd. — Form 10-K Summary
Reporting period: Fiscal year ended May 27, 2023 (52 weeks), filed July 31, 2023. The filing is an FY2023 annual report, not a fiscal 2022 Q4 report; it also provides unaudited FY2023 fourth-quarter results. Richardson Electronics supplies engineered electronic solutions and components, customized displays, and diagnostic-imaging replacement products through four segments: Power and Microwave Technologies (PMT), Green Energy Solutions (GES), Canvys, and Healthcare.
Financial performance
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $262.7 million | $224.6 million |
| Gross profit / margin | $83.7 million / 31.9% | $71.7 million / 31.9% |
| SG&A | $58.7 million (22.4% of sales) | $55.7 million (24.8% of sales) |
| Operating income | $25.0 million | $16.0 million |
| Net income | $22.3 million | $17.9 million |
| Diluted EPS, common shares | $1.55 | $1.31 |
| Cash from operating activities | $(8.2) million | $1.9 million |
Revenue rose 16.9% and net income rose 24.6%. Gross margin was unchanged year over year; lower SG&A as a share of sales and increased revenue supported higher operating income. FY2023 net income included a $0.9 million R&D tax-credit benefit recorded in the fourth quarter.
FY2023 Q4: Sales were $58.8 million versus $61.6 million in FY2022 Q4; net income was $4.1 million versus $8.3 million. FY2023 Q4 sales and net income were also below FY2023 Q3 ($70.4 million and $6.3 million, respectively).
Segments and material changes
- PMT: Sales increased 5.7% to $164.3 million; gross margin increased to 32.9% from 32.7%. Management cited semiconductor wafer-fabrication and RF/microwave demand.
- GES: Sales increased 110.5% to $47.6 million, driven mainly by wind-turbine products and EV battery modules. Gross margin declined to 28.8% from 32.0% on product mix. GES was separated from PMT as a reportable segment in FY2023; prior periods were recast.
- Canvys: Sales increased 11.8% to $39.3 million, while gross margin decreased to 31.5% from 32.0%, primarily due to mix. Management also cited residual pandemic-related economic effects on margins.
- Healthcare: Sales were nearly flat at $11.4 million; gross margin improved to 30.7% from 21.2%, mainly from better manufacturing absorption and lower component scrap.
Cash, liquidity, debt, and capital allocation
- Cash and cash equivalents were $25.0 million at year-end, down from $35.5 million; FY2022 also included $5.0 million of current investments, which were liquidated in FY2023.
- Operating cash use of $8.2 million primarily reflected a $30.5 million inventory increase and lower accounts payable and accrued liabilities, despite $22.3 million of net income. Inventory was $110.4 million, net of a $5.9 million reserve, versus $80.4 million a year earlier.
- Capital expenditures were $7.4 million. The company paid $3.3 million in dividends; the quarterly dividend was $0.06 per common share and $0.054 per Class B share. Future dividends remain at the board’s discretion.
- Total liabilities were $38.7 million, including $2.5 million of lease liabilities. No borrowings were outstanding under the new $30 million, three-year secured revolving credit facility with PNC at year-end. The company reported covenant compliance.
- Management said existing liquidity and expected operating cash flows should meet known requirements through the next 12 months.
Outlook, risks, and unusual items
The filing provides no specific sales, earnings, or margin guidance. Management’s stated strategy emphasizes growth in GES, Healthcare, and power-conversion businesses; execution and profitability of these initiatives are uncertain.
- Inventory is a significant exposure: technology changes, declining demand for some legacy products, and forecasting errors could require further write-downs. Inventory-reserve estimation for PMT was identified as a critical audit matter; the year-end inventory balance was $110.4 million.
- Customer and supplier concentration warrant attention: one PMT customer generated $31.2 million, or 12% of FY2023 sales, and represented 20% of year-end receivables. One supplier accounted for 11% of cost of sales.
- Supply-chain, component availability, freight, inflation, tariffs, and geopolitical disruptions may affect costs, delivery, demand, and margins. The company said residual pandemic effects continued to weigh on Canvys margins and product-development schedules.
- Approximately 58% of sales were outside the United States. The company uses no currency hedges; an unfavorable 10% movement in foreign exchange rates was estimated to reduce FY2023 foreign-currency-denominated sales by $12.2 million.
- Other disclosed risks include customer credit and collection exposure, cybersecurity and privacy compliance, product liability, international trade and regulatory requirements, and dependence on key personnel. CEO Edward J. Richardson controlled approximately 62% of voting power as of July 25, 2023.
- The company recorded a $1.6 million settlement expense in FY2021 relating to claims by Varex Imaging; it did not admit liability. The filing reports no current legal proceedings. BDO issued unqualified opinions on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Whether the substantial inventory build converts into sales and cash without additional obsolescence charges.
- Whether GES growth can sustain or recover segment margins, and whether FY2023’s growth drivers continue.
- How operating cash flow and working-capital requirements develop after the FY2023 cash outflow.
- The durability of the concentrated customer relationship and supply from the company’s key supplier.
- Whether Canvys margins, foreign-exchange exposure, and international supply-chain conditions improve or deteriorate.
- That period comparisons use the FY2023 reporting basis, including the reclassification of GES from PMT.